Amarin Corporation plc (ADR) Stock Xetra
Equities
EH3A
US0231112063
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
Sales 2024 * | 202M 189M 276M | Sales 2025 * | 215M 201M 294M | Capitalization | 292M 273M 400M |
---|---|---|---|---|---|
Net income 2024 * | -70M -65.33M -95.75M | Net income 2025 * | -64M -59.73M -87.54M | EV / Sales 2024 * | 1.23 x |
Net cash position 2024 * | 43.92M 40.99M 60.07M | Net cash position 2025 * | 159M 148M 217M | EV / Sales 2025 * | 0.62 x |
P/E ratio 2024 * |
-4.03
x | P/E ratio 2025 * |
-4.28
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.48% |
Latest transcript on Amarin Corporation plc (ADR)
Managers | Title | Age | Since |
---|---|---|---|
Aaron Berg
CEO | Chief Executive Officer | 61 | 12-10-31 |
Thomas Reilly
DFI | Director of Finance/CFO | 52 | 22-06-19 |
Compliance Officer | 55 | 11-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Louis Sterling
BRD | Director/Board Member | 45 | 23-02-27 |
Odysseas Kostas
CHM | Chairman | 49 | 23-02-27 |
Keith Horn
BRD | Director/Board Member | 66 | 23-02-27 |
1st Jan change | Capi. | |
---|---|---|
+15.85% | 121B | |
+18.91% | 112B | |
+4.43% | 22.57B | |
-18.63% | 20.82B | |
-13.76% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+1.75% | 13.17B | |
+28.07% | 11.11B |
- Stock Market
- Equities
- AMRN Stock
- EH3A Stock